$40.96
0.51% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Tarsus Pharmaceuticals Inc Stock price

$40.96
-3.24 7.33% 1M
-11.18 21.44% 6M
-14.41 26.02% YTD
+8.36 25.64% 1Y
+24.96 156.00% 5Y
+24.96 156.00% 10Y
+24.96 156.00% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.21 0.51%
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Key metrics

Market capitalization $1.72b
Enterprise Value $1.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.93
P/S ratio (TTM) P/S ratio 7.36
P/B ratio (TTM) P/B ratio 5.02
Revenue growth (TTM) Revenue growth 449.04%
Revenue (TTM) Revenue $233.67m
EBIT (operating result TTM) EBIT $-111.11m
Free Cash Flow (TTM) Free Cash Flow $-72.87m
Cash position $407.92m
EPS (TTM) EPS $-2.66
P/E forward negative
P/S forward 4.30
EV/Sales forward 3.46
Short interest 19.15%
Show more

Is Tarsus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Tarsus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Tarsus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
234 234
449% 449%
100%
- Direct Costs 16 16
404% 404%
7%
217 217
453% 453%
93%
- Selling and Administrative Expenses 271 271
86% 86%
116%
- Research and Development Expense 56 56
11% 11%
24%
-110 -110
29% 29%
-47%
- Depreciation and Amortization 1.42 1.42
35% 35%
1%
EBIT (Operating Income) EBIT -111 -111
29% 29%
-48%
Net Profit -105 -105
29% 29%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about Tarsus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tarsus Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
14 days ago
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Positive
Seeking Alpha
about one month ago
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compa...
Neutral
GlobeNewsWire
about one month ago
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences:
More Tarsus Pharmaceuticals Inc News

Company Profile

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Head office United States
CEO Bobak Azamian
Employees 244
Founded 2017
Website www.tarsusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today